Suppr超能文献

前列腺癌患者的偏好和治疗决策:来自全州范围的泌尿外科质量改进合作的结果。

Patient Preferences and Treatment Decisions for Prostate Cancer: Results From A Statewide Urological Quality Improvement Collaborative.

机构信息

Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI.

Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI.

出版信息

Urology. 2021 Sep;155:55-61. doi: 10.1016/j.urology.2021.04.020. Epub 2021 Apr 29.

Abstract

OBJECTIVES

To examine the relationship between influential factors and treatment decisions among men with newly diagnosed prostate cancer (PCa).

METHODS

We identified men in the Michigan Urological Surgery Improvement Collaborative registry diagnosed with localized PCa between 2018-2020 who completed Personal Patient Profile-Prostate. We analyzed the proportion of active surveillance (AS) between men who stated future bladder, bowel, and sexual problems (termed influential factors) had "a lot of influence" on their treatment decisions versus other responses. We also assessed the relationship between influential factors, confirmatory testing results and choice of AS.

RESULTS

A total of 509 men completed Personal Patient Profile-Prostate. Treatment decisions aligned with influential factors for 88% of men with favorable risk and 49% with unfavorable risk PCa. A higher proportion of men who identified bladder, bowel and sexual concerns as having "a lot of influence" on their treatment decision chose AS, compared with men with other influential factors, although not statistically significant (44% vs 35%, P = .11). Similar results were also found when men were stratified based on PCa risk groups (favorable risk: 78% vs 67%; unfavorable risk: 17% vs 9%, respectively). Despite a small sample size, a higher proportion of men with non-reassuring confirmatory testing selected AS if influential factors had "a lot of influence" compared to "no influence" on their treatment decisions.

CONCLUSION

Men's concerns for future bladder, bowel, and sexual function problems, as elicited by a decision aid, may help explain treatment selection that differs from traditional clinical recommendation.

摘要

目的

探讨新诊断前列腺癌(PCa)患者的影响因素与治疗决策之间的关系。

方法

我们从密歇根州泌尿外科学术改进协作注册中心确定了 2018-2020 年间被诊断为局限性 PCa 且完成个人患者特征-前列腺评估的男性患者。我们分析了表示未来膀胱、肠道和性功能问题(称为影响因素)对其治疗决策“有很大影响”的男性与其他反应的男性之间主动监测(AS)的比例。我们还评估了影响因素、确认性检测结果与 AS 选择之间的关系。

结果

共有 509 名男性完成了个人患者特征-前列腺评估。对于低危 PCa 患者,88%的治疗决策与影响因素一致;而对于高危 PCa 患者,49%的治疗决策与影响因素一致。与具有其他影响因素的男性相比,认为膀胱、肠道和性功能问题对其治疗决策有“很大影响”的男性选择 AS 的比例更高,尽管差异无统计学意义(44% vs 35%,P = 0.11)。当按 PCa 风险组对男性进行分层时,也得到了类似的结果(低危组:78% vs 67%;高危组:17% vs 9%)。尽管样本量较小,但与“无影响”相比,如果影响因素对其治疗决策“有很大影响”,则有更多非明确性确认性检测结果的男性选择 AS。

结论

决策辅助工具中男性对未来膀胱、肠道和性功能问题的担忧可能有助于解释与传统临床建议不同的治疗选择。

相似文献

6
Concordance between influential adverse treatment outcomes and localized prostate cancer treatment decisions.
BMC Med Inform Decis Mak. 2022 Aug 24;22(1):223. doi: 10.1186/s12911-022-01972-w.
7
Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Urology. 2015 Nov;86(5):901-5. doi: 10.1016/j.urology.2015.08.024. Epub 2015 Sep 7.
8
The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide.
Eur Urol. 2023 Apr;83(4):307-310. doi: 10.1016/j.eururo.2022.05.028. Epub 2022 Jun 7.
9
Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Eur Urol. 2015 Jan;67(1):44-50. doi: 10.1016/j.eururo.2014.08.024. Epub 2014 Aug 24.
10
Early prostate cancer--which treatment do men prefer and why?
BJU Int. 2011 Jun;107(11):1762-8. doi: 10.1111/j.1464-410X.2010.09833.x. Epub 2010 Nov 17.

引用本文的文献

2
Patients' perception on quality of care for prostate cancer at tertiary hospitals in Tanzania: a qualitative study.
Front Oncol. 2024 Dec 9;14:1492302. doi: 10.3389/fonc.2024.1492302. eCollection 2024.
3
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4.
5
Concordance between influential adverse treatment outcomes and localized prostate cancer treatment decisions.
BMC Med Inform Decis Mak. 2022 Aug 24;22(1):223. doi: 10.1186/s12911-022-01972-w.

本文引用的文献

1
Implementation of prostate cancer treatment decision aid in Michigan: a qualitative study.
Implement Sci Commun. 2021 Mar 6;2(1):27. doi: 10.1186/s43058-021-00125-w.
2
3
Shared Decision-making in Urologic Practice: Results From the 2019 AUA Census.
Urology. 2020 Nov;145:66-72. doi: 10.1016/j.urology.2020.06.078. Epub 2020 Aug 7.
4
Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience.
J Urol. 2020 Dec;204(6):1119-1121. doi: 10.1097/JU.0000000000001308. Epub 2020 Jul 27.
5
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
Interventions for increasing the use of shared decision making by healthcare professionals.
Cochrane Database Syst Rev. 2018 Jul 19;7(7):CD006732. doi: 10.1002/14651858.CD006732.pub4.
9
Making their decisions for prostate cancer treatment: Patients' experiences and preferences related to process.
Can Urol Assoc J. 2018 Oct;12(10):337-343. doi: 10.5489/cuaj.5113. Epub 2018 May 28.
10
Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.
Am J Mens Health. 2018 Sep;12(5):1719-1727. doi: 10.1177/1557988318785741. Epub 2018 Jul 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验